Cleveland BioLabs and Incuron Announce Growth of Curaxin CBL0137 Patent Portfolio With U.S. Composition of Matter Patent

Cleveland BioLabs, Inc.

and Incuron LLC, a joint venture between the CBLI and Bioprocess Capital Ventures, announce the issuance of a composition of matter patent for Curaxin CBL0137 in the U.S. In 2014, Incuron secured a composition of matter patent in the U.S., Patent Number 8,765,738, that covers composition of matter of CBL0137 and related curaxin compounds and provides the company protection to at least 2030. This is Incuron's second issued U.S. patent concerning CBL0137. Additional pending U.S. and international patent applications include claims to methods of use in oncology as well as various diagnostic methods. Further, Incuron has secured similar composition of matter patents covering CBL0137 in a number of important foreign markets, including Europe, China, and Russia. Incuron has also received notice that its composition of matter patent application will be granted in Japan soon. Andrey Leonov, Ph.D., Chief Executive Officer of Incuron, commented, "Strengthening CBL0137's patent portfolio is a key facet of our partnering strategy. CBL0137 offers a novel mechanism of action and we believe that it has the potential to be used as a targeted therapeutic in a broad spectrum of cancers. Consistent with this broad potential applicability of CBL0137, these new composition of matter patents are not limited to any specific disease and therefore, along with our exciting recent clinical data, put Incuron in an excellent position to advance this unique drug."